Zorevunersen not checked
Stoke Therapeutics, Inc · STK-001
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Treatment Period 1: Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg on Day 169 and Day 281. Treatment Period 2: Group assigned to zorevunersen in Treatment Period 1 will receive 45 mg of zorevunersen on Day…”In the company’s words, NCT06872125 on ClinicalTrials.gov
- Tested for
- Dravet Syndrome (2 trials)
- Main trialPhase 3
- “The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.”In the company’s words, NCT06872125 on ClinicalTrials.gov
- Other names
- STK-001
Other drugs for Dravet Syndrome
- LP352Longboard Pharmaceuticals · Phase 3
- Clemizole HClEpygenix · Phase 3
- ETX101Encoded Therapeutics · Phase 1/2
- ION337Ionis Pharmaceuticals, Inc. · Phase 1/2
- BMB-101Bright Minds Biosciences · Phase 2
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up2
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Mar 2027 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | |
| Phase 2Active, not recruiting | 31 Mar 2029 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome | |
| Phase 1/2Completed | 14 Nov 2023 | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026